Key result
Clinically relevant bleeding was independently associated with mortality in cancer patients, including intracranial hemorrhage (HR 4.17; 95% CI 4.11-4.24) and gastrointestinal bleeding (HR 2.52).
Why the study?
What is the incidence of clinically relevant bleeding and its association with mortality in individuals with cancer?
Population
2,455,332 individuals with incident cancer encounters from 215 US health systems between 2018 and 2024
Design
Cohort
Follow-up
12 months after cancer diagnosis
Authors
Loading...
Clinically relevant bleeding is a frequent complication in cancer patients, particularly those on anticoagulants, and is strongly associated with increased mortality.
Cohort (n=2,455,332)
Yes
What is the incidence of clinically relevant bleeding and its association with mortality in individuals with cancer?
Hazard Ratio: 4.17 (95% CI 4.11–4.24)
Clinically relevant bleeding is a frequent complication in cancer patients, particularly those on anticoagulants, and is strongly associated with increased mortality.
Lim et al. (2026) conducted a cohort in Cancer (n=2,455,332). Clinically relevant bleeding vs. No clinically relevant bleeding was evaluated on Mortality (HR 4.17, 95% CI 4.11-4.24). Clinically relevant bleeding was independently associated with mortality in cancer patients, including intracranial hemorrhage (HR 4.17; 95% CI 4.11-4.24) and gastrointestinal bleeding (HR 2.52).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: